Oncogenic Activity of Retinoic Acid Receptor γ Is Exhibited through Activation of the Akt/NF-κB and Wnt/β-Catenin Pathways in Cholangiocarcinoma

REFERENCES

• Aljiffry M, Walsh MJ, Molinari M. 2009. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J. Gastroenterol. 15:4240–4262.
   PubMed Web of Science ®Google Scholar
• Khan SA, Toledano MB, Taylor-Robinson SD. 2008. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB 10:77–82.
   PubMed Web of Science ®Google Scholar
• Gronemeyer H, Gustafsson JA, Laudet V. 2004. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3:950–964.
   PubMed Web of Science ®Google Scholar
• Marinelli A, Bossi D, Pelicci PG, Minucci S. 2007. A redundant oncogenic potential of the retinoic receptor (RAR) alpha, beta and gamma isoforms in acute promyelocytic leukemia. Leukemia 21:647–650.
   PubMed Web of Science ®Google Scholar
• Purton LE, Dworkin S, Olsen GH, Walkley CR, Fabb SA, Collins SJ, Chambon P. 2006. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J. Exp. Med. 203:1283–1293.
   PubMed Web of Science ®Google Scholar
• Zhao X, Demary K, Wong L, Vaziri C, McKenzie AB, Eberlein TJ, Spanjaard RA. 2001. Retinoic acid receptor-independent mechanism of apoptosis of melanoma cells by the retinoid CD437 (AHPN). Cell Death Differ. 8:878–886.
   PubMedGoogle Scholar
• Goranov BB, Campbell Hewson QD, Pearson AD, Redfern CP. 2006. Overexpression of RARgamma increases death of SH-SY5Y neuroblastoma cells in response to retinoic acid but not fenretinide. Cell Death Differ. 13:676–679.
   PubMedGoogle Scholar
• Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE. 2007. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 129:1097–1110.
   PubMed Web of Science ®Google Scholar
• Zhao X, Graves C, Ames SJ, Fisher DE, Spanjaard RA. 2009. Mechanism of regulation and suppression of melanoma invasiveness by novel retinoic acid receptor-gamma target gene carbohydrate sulfotransferase 10. Cancer Res. 69:5218–5225.
   PubMedGoogle Scholar
• Chen CF, Goyette P, Lohnes D. 2004. RARgamma acts as a tumor suppressor in mouse keratinocytes. Oncogene 23:5350–5359.
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Kim SW, Cheon K, Tabassam FH, Yoon JH, Koo JS. 2006. Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. Mol. Biol. Cell 17:566–575.
   PubMed Web of Science ®Google Scholar
• Hughes PJ, Zhao Y, Chandraratna RA, Brown G. 2006. Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways. J. Cell. Biochem. 97:327–350.
   PubMed Web of Science ®Google Scholar
• Masia S, Alvarez S, de Lera AR, Barettino D. 2007. Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor. Mol. Endocrinol. 21:2391–2402.
   PubMedGoogle Scholar
• Dey N, De PK, Wang M, Zhang H, Dobrota EA, Robertson KA, Durden DL. 2007. CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Mol. Cell. Biol. 27:4179–4197.
   PubMedGoogle Scholar
• Yan TD, Wu H, Zhang HP, Lu N, Ye P, Yu FH, Zhou H, Li WG, Cao X, Lin YY, He JY, Gao WW, Zhao Y, Xie L, Chen JB, Zhang XK, Zeng JZ. 2010. Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res. 70:2285–2295.
   PubMed Web of Science ®Google Scholar
• Shen DY, Zhan YH, Wang QM, Rui G, Zhang ZM. 2013. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma. Liver Int. 33:137–148.
   PubMed Web of Science ®Google Scholar
• Zhou X, Yang J, Wang Y, Li W, Li-Ling J, Deng Y, Zhang M. 2012. Cucurbitacin B inhibits 12-O-tetradecanoylphorbol 13-acetate-induced invasion and migration of human hepatoma cells through inactivating mitogen-activated protein kinase and PI3K/Akt signal transduction pathways. Hepatol. Res. 42:401–411.
   PubMedGoogle Scholar
• Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, Katano M. 2010. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res. 30:2041–2048.
   PubMed Web of Science ®Google Scholar
• Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D, Beckmann JS, Joseph JM, Muhlethaler-Mottet A, Gross N. 2009. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 28:2245–2256.
   PubMed Web of Science ®Google Scholar
• Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. U. S. A. 96:5522–5527.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang X, Wu X, Li W, Su P, Cheng H, Xiang L, Gao P, Zhou G. 2012. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/beta-catenin pathway. Cancer Lett. 323:106–113.
   PubMed Web of Science ®Google Scholar
• Fukunaka K, Saito T, Wataba K, Ashihara K, Ito E, Kudo R. 2001. Changes in expression and subcellular localization of nuclear retinoic acid receptors in human endometrial epithelium during the menstrual cycle. Mol. Hum. Reprod. 7:437–446.
   PubMedGoogle Scholar
• Albrechtsson E, Ohlsson B, Axelson J. 2002. The expression of retinoic acid receptors and the effects in vitro by retinoids in human pancreatic cancer cell lines. Pancreas 25:49–56.
   PubMed Web of Science ®Google Scholar
• Chakravarti N, Lotan R, Diwan AH, Warneke CL, Johnson MM, Prieto VG. 2007. Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin. Cancer Res. 13:4817–4824.
   PubMedGoogle Scholar
• Kumar A, Kaur J, Chattopadhyay TK, Mathur M, Ralhan R. 2004. Differential expression of retinoic acid receptors in normal and malignant esophageal tissues. J. Exp. Ther. Oncol. 4:1–8.
   PubMedGoogle Scholar
• Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM, Berry DP. 2009. Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur. J. Cancer 45:33–47.
   PubMed Web of Science ®Google Scholar
• Hahnvajanawong C, Ketnimit S, Pattanapanyasat K, Anantachoke N, Sripa B, Pinmai K, Seubwai W, Reutrakul V. 2012. Involvement of p53 and nuclear factor-kappaB signaling pathway for the induction of G1-phase cell cycle Arrest of cholangiocarcinoma cell lines by isomorellin. Biol. Pharm. Bull. 35:1914–1925.
   PubMed Web of Science ®Google Scholar
• Batheja N, Suriawinata A, Saxena R, Ionescu G, Schwartz M, Thung SN. 2000. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Mod. Pathol. 13:1265–1268.
   PubMedGoogle Scholar
• Itatsu K, Sasaki M, Yamaguchi J, Ohira S, Ishikawa A, Ikeda H, Sato Y, Harada K, Zen Y, Sato H, Ohta T, Nagino M, Nimura Y, Nakanuma Y. 2009. Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. Am. J. Pathol. 174:829–841.
   PubMed Web of Science ®Google Scholar
• Sirica AE. 2005. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41:5–15.
   PubMed Web of Science ®Google Scholar
• Liu ZH, He YP, Zhou Y, Zhang P, Qin H. 2011. Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. Mol. Biol. Rep. 38:3075–3082.
   PubMedGoogle Scholar
• Sadana P. 2012. Noncanonical mechanisms to regulate nuclear receptor signaling. Future Med. Chem. 4:1307–1333.
   PubMedGoogle Scholar
• Prakobwong S, Gupta SC, Kim JH, Sung B, Pinlaor P, Hiraku Y, Wongkham S, Sripa B, Pinlaor S, Aggarwal BB. 2011. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis 32:1372–1380.
   PubMed Web of Science ®Google Scholar
• Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, Schmid KW, Baba HA. 2007. AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J. Gastroenterol. 13:6470–6477.
   PubMed Web of Science ®Google Scholar
• Sugimachi K, Taguchi K, Aishima S, Tanaka S, Shimada M, Kajiyama K, Tsuneyoshi M. 2001. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod. Pathol. 14:900–905.
   PubMed Web of Science ®Google Scholar
• Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, Shimizu Y, Itamoto T, Arihiro K, Okajima M, Asahara T. 2005. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int. J. Oncol. 27:973–980.
   PubMed Web of Science ®Google Scholar
• Clevers H, Nusse R. 2012. Wnt/beta-catenin signaling and disease. Cell 149:1192–1205.
   PubMed Web of Science ®Google Scholar
• Yasuhara R, Yuasa T, Williams JA, Byers SW, Shah S, Pacifici M, Iwamoto M, Enomoto-Iwamoto M. 2010. Wnt/beta-catenin and retinoic acid receptor signaling pathways interact to regulate chondrocyte function and matrix turnover. J. Biol. Chem. 285:317–327.
   PubMed Web of Science ®Google Scholar